Rusty microglia: trainers of innate immunity in Alzheimer's disease by Sfera, Adonis et al.
REVIEW
published: 04 December 2018
doi: 10.3389/fneur.2018.01062
Frontiers in Neurology | www.frontiersin.org 1 December 2018 | Volume 9 | Article 1062
Edited by:
Isabella Zanella,
Università degli Studi di Brescia, Italy
Reviewed by:
Ilias Kounatidis,
Diamond Light Source,
United Kingdom
Po-Wah So,
King’s College London,
United Kingdom
*Correspondence:
Adonis Sfera
dr.sfera@gmail.com
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neurology
Received: 09 August 2018
Accepted: 21 November 2018
Published: 04 December 2018
Citation:
Sfera A, Gradini R, Cummings M,
Diaz E, Price AI and Osorio C (2018)
Rusty Microglia: Trainers of Innate
Immunity in Alzheimer’s Disease.
Front. Neurol. 9:1062.
doi: 10.3389/fneur.2018.01062
Rusty Microglia: Trainers of Innate
Immunity in Alzheimer’s Disease
Adonis Sfera 1,2*, Roberto Gradini 3, Michael Cummings 2, Eddie Diaz 2, Amy I. Price 4 and
Carolina Osorio 1
1 Psychiatry, Loma Linda University, Loma Linda, CA, United States, 2 Patton State Hospital, San Bernardino, CA,
United States, 3Department of Pathology, La Sapienza University of Rome, Rome, Italy, 4 Evidence Based Medicine,
University of Oxford, Oxford, United Kingdom
Alzheimer’s disease, the most common form of dementia, is marked by progressive
cognitive and functional impairment believed to reflect synaptic and neuronal loss.
Recent preclinical data suggests that lipopolysaccharide (LPS)-activated microglia may
contribute to the elimination of viable neurons and synapses by promoting a neurotoxic
astrocytic phenotype, defined as A1. The innate immune cells, including microglia and
astrocytes, can either facilitate or inhibit neuroinflammation in response to peripherally
applied inflammatory stimuli, such as LPS. Depending on previous antigen encounters,
these cells can assume activated (trained) or silenced (tolerized) phenotypes, augmenting
or lowering inflammation. Iron, reactive oxygen species (ROS), and LPS, the cell wall
component of gram-negative bacteria, are microglial activators, but only the latter can
trigger immune tolerization. In Alzheimer’s disease, tolerization may be impaired as
elevated LPS levels, reported in this condition, fail to lower neuroinflammation. Iron
is closely linked to immunity as it plays a key role in immune cells proliferation and
maturation, but it is also indispensable to pathogens andmalignancies which compete for
its capture. Danger signals, including LPS, induce intracellular iron sequestration in innate
immune cells to withhold it from pathogens. However, excess cytosolic iron increases the
risk of inflammasomes’ activation, microglial training and neuroinflammation. Moreover,
it was suggested that free iron can awaken the dormant central nervous system
(CNS) LPS-shedding microbes, engendering prolonged neuroinflammation that may
override immune tolerization, triggering autoimmunity. In this review, we focus on
iron-related innate immune pathology in Alzheimer’s disease and discuss potential
immunotherapeutic agents for microglial de-escalation along with possible delivery
vehicles for these compounds.
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HIGHLIGHTS
- LPS activates microglial TLRs, training these cells excessively
and triggering the release of C1q, TNF-alpha, and IL-1 alpha,
biomolecules associated with autoimmunity.
- A1 astrocytes, likely autoimmune, eliminate viable neurons
and oligodendrocytes, contributing to Alzheimer’s disease
neuronal and synaptic loss.
- LPS, a danger signal, promotes intracellular iron
sequestration, increasing the risk of ROS. LPS also promotes
ferritinophagy, increasing the free intracellular iron levels.
- ROS and iron activate NLRP3 inflammasomes, generating
prolonged inflammation which may override microglial
tolerization, engendering autoimmune A1 astrocytes.
- Promoting tolerization and lowering training may de-escalate
microglia, lowering the risk of neuronal loss and Alzheimer’s
disease.
INTRODUCTION
Alzheimer’s disease (AD), the most common form of dementia,
is marked by progressive memory impairment and functional
decline believed to reflect synaptic and neuronal loss. Elimination
of these structures may be carried out by an aggressive
astrocytic phenotype, defined as A1. Preclinical studies show
that LPS-activated microglia enable the conversion of trophic
to A1 astrocytes by releasing several cytokines, including tumor
necrosis factor alpha (TNF-alpha), interlukin-1 alpha (IL-1
alpha), and complement component C1q. These molecules alter
astrocytic transcriptomes, promoting the neurotoxic A1 cells
observed to engage in the phagocytosis of healthy neurons and
oligodendrocytes, contributing to their loss (1). In this article we
take the position that A1 astrocytes are autoimmune in nature,
resulting from the prolonged microglial activation that overrides
LPS tolerization.
LPS tolerization refers to the absence of an inflammatory
response after repeated or prolonged exposure to this microbial
endotoxin as re-challenged “tolerant” innate immune cells are
incapable of immunological activation. This is relevant to AD
because the constantly elevated brain LPS levels, detected in
this disorder, fail to trigger microglial tolerization and lower
neuroinflammation (2, 3).
Excess LPS in the brain microenvironment, a danger signal,
is detected by microglial TLRs which activate the pathogen-
mediated iron sequestration via hepcidin-ferroportin axis (4)
(Figure 1). Indeed, recent neuroimaging studies detected iron-
containing microglia in the hippocampi of AD patients, likely
reflecting LPS-triggered iron sequestration (5).
The source of brain LPS is unclear at this time, but it has
been hypothesized that it may derive from the gastrointestinal
(GI) tract microbial community. These bacteria were found to
lie dormant in various tissues, possibly including the brain, for
prolonged periods of time restrained by the lack of free iron (3, 6).
Later in life, impaired iron homeostasis caused by aging and/or
defective ferritinophagymay provide thesemicrobes with enough
metal to resume their growth and LPS shedding, engendering
inflammatory neuropathology (6).
Iron is closely linked to immunity as it plays a key role
in immune cells proliferation and maturation, but it is also
indispensable to pathogens and malignancies which compete for
its capture (discussed in The Trained Arm of Innate Immunity
section). To safeguard iron, innate immune cells, including
microglia and astrocytes, sequestrate it intracellularly bound
to cytosolic and mitochondrial ferritin, an arrangement which
can generate excessive ROS and inflammation when disrupted
(4). Indeed, iron-ferritin dissociation was demonstrated in AD
animal models in which LPS-induced ferritinophagy increased
intracellular free iron, engendering neuroinflammation (7, 8).
Moreover, iron-damaged mitochondria were shown to act as
danger signals, activating the inflammatory cascade by igniting
inflammasomes, including NLRP3 (9).
LPS-activated microglia release cytokines, including TNF-
alpha, IL-1 alpha, and C1q, that have been associated with
autoimmune inflammation, an association that led to the
development of vaccines, including anti-TNF-alpha antibodies
(for the treatment of autoimmune disorders) and anti-C1q
antibody, currently in phase I trials for both AD and
autoimmunity (10, 11).
In contrast to immune tolerization which may be an adaptive
mechanism to prevent autoimmune inflammation, allowing the
clearance of damaged self-components, immune training may
serve the purpose of overriding immune anergy encountered in
various pathologies, including sepsis and cancer (12, 13). Indeed,
the peripheral and central innate immune cells are engaged in
a balancing act as they must be sufficiently trained to effectively
defend the host against pathogens and malignancies, while
at the same time tolerant enough to accept self-components,
food, the fetus and commensal microbes. Disruption of this
fine equilibrium may either cause unchecked inflammation or
excessive tolerance (12). Iron interferes with this balance by
promoting activation and inflammation, a property exploited
in oncology to train tumor-associated macrophages (TAMs) in
fighting malignant cells (14). On the other hand, iron chelators
oppose training, providing therapeutic benefit in AD. Indeed,
deferiprone, currently in phase 2 clinical trials, may soon
become the first FDA approved iron chelator indicated for AD
(15). Along these lines, a recent preclinical study demonstrated
that in response to peripherally applied inflammatory stimuli,
microglia can undergo either activation (training) or tolerization,
the former augmenting, the latter lowering neuroinflammation
(13). This is important for AD because this study also found
that training increases while tolerization decreases β-amyloid
accumulation, suggesting that central tolerance can be promoted
by peripheral stimulation, comprising a novel therapeutic
strategy (13). Previous AD studies are in line with this model
as it was demonstrated that immune trained subjects (positive
for TNF-alpha) presented with memory loss, while the tolerized
patients (TNF-alpha negative) lacked cognitive deterioration
(16). Moreover, trained microglia and astrocytes were found able
to undergo transcriptomic alterations, morphing into antigen
presenting cells (APCs) that can establish immunologic synapses
with infiltrating peripheral lymphocytes, further perpetuating
neuroinflammation (17).
Traditionally, immunological memory has been associated
with adaptive immunity, however novel studies indicate that
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FIGURE 1 | LPS, a danger signal, binds to TLRs of microglia, inducing pathogen-mediated intracellular iron sequestration. LPS also promotes astrocytic hepcidin
synthesis which via FPN prevents iron egress. In addition, LPS inhibits TREM-2 expressed on microglial cells. Intracellular iron is stored in Ft and mtFt. Iron can
dissociate from ferritins via ferritinophagy, augmenting the free iron (labile iron pool). Unbound iron directly and indirectly (via ROS) activates NLRP3 and NF-kB,
inducing microglial activation (training). Microglial release of cytokines, including TNF-alpha, IL-1, and C1q induces A1 astrocytes shown to engage in the
phagocytosis of viable neurons and oligodendrocytes, contributing to neuronal loss and possibly AD.
innate immune cells, including microglia and astrocytes can
“recall” prior vaccinations or infections (13). For example,
β-glucan, a cell wall component of Candida Albicans and
bacillus Calmette-Guerin (BCG), was shown to train monocytes,
improving the outcome of sepsis-induced immune paralysis (18).
Indeed, the development of treatments based on innate immune
memory manipulation has been encouraged by the recent FDA
approval of immune training-inducers, the BCG vaccine for
the treatment and prophylaxis of urinary bladder carcinoma in
situ (CIS) and muramyl tripeptide for osteosarcoma (19). Along
these lines, innate immune memory manipulation may improve
AD outcome by de-escalating microglia via peripherally-
applied tolerizing stimuli (13). Since tolerized immunity, unlike
immunosuppression, is antigen specific and natural, harnessing
it may not only benefit AD but also cancer and autoimmune
disorders (20, 21). The recent finding that altered endogenous
molecules, including dysfunctional mitochondria, can trigger
microglial training will likely result in novel AD strategies,
including mitophagy-activating therapeutics (22).
In this article we look beyond iron chelators, focusing
on lowering the consequences of iron pathology,
especially microglial training and defective tolerization.
The immunotherapeutic agents discussed here include
inflammasome inhibitors, histone deacetylase inhibitors,
activators of co-inhibitory receptors, acetylcholinesterase
inhibitors and selective serotonin reuptake inhibitors.
IRON HOMEOSTASIS AND THE INNATE
IMMUNE SYSTEM
Iron is an indispensable but potentially toxic trace element and
for this reason it has to be circulated throughout the body
attached to its carrier protein, transferrin (Tf). Dietary iron is
absorbed in the gut by crossing the enterocyte brush border
membrane via divalent metal-ion transporter 1 (DMT-1). After
conversion from ferrous to ferric iron by hephaestin and/or
ceruloplasmin it is exported through the basolateral membrane
via ferroportin (FPN) channels (23).
Novel studies have demonstrated that gram-negative
commensal gut microbes are able to generate more than one
type of LPS, thus activating or inhibiting innate immune
responses (24). For example, Escherichia coli LPS was found
to be an activator of innate immunity, while LPS derived
from Bacteroides dorei was linked to immune tolerance (25).
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Interestingly, Bacteroides fragilis LPS (BF-LPS) was shown to
contribute to autoimmune pathology by selectively inhibiting
innate immune tolerization (26). Since the host and microbes
share a common iron pool, its availability is directly linked to the
survival and growth of the LPS-shedding bacteria.
Iron enters the CNS together with Tf (iron-Tf complex)
by binding to transferrin receptor-1 (TFR-1) expressed by the
endothelial cells of brain capillaries. After crossing into the
cytosol of these cells and satisfying their metabolic needs,
excess iron is stored in the cytosolic and mitochondrial ferritin.
The remaining iron is exported via FPN into the extracellular
space (27).
One of the key roles of the innate immune system is
pathogen-mediated intracellular iron sequestration to deny
it to bacteria and malignancies which are dependent on
this biometal for growth (discussed in The Trained Arm
of Innate Immunity section). Iron sequestration is initiated
in response to exogenous and endogenous danger signals,
consisting of pathogen-associated molecular patterns (PAMPs)
or, damage-associated molecular patterns (DAMPs), respectively.
For example, LPS, the cell wall component of gram-negative
bacteria, is a PAMP that activates microglial TLR-4. In contrast,
the endogenously produced ROS is a DAMP that activates
the cytosolic inflammasome NOD-like receptor pyrin domain-
containing-3 (NLRP3) (28). Iron, itself and/or iron-induced ROS
were shown to activate NLRP3 inflammasomes, engendering
neuroinflammation (9) (Figure 1).
Iron enters neurons via DMT-1 and TFR-1 receptors but
can only exit these cells through FPN, a receptor controlled
by hepcidin, the master regulator of iron metabolism. Hepcidin
is biosynthesized in the liver, but since only a small fraction
of this this peptide hormone crosses the brain-blood barrier
(BBB), the brain produces its own hepcidin. High hepcidin
levels are associated with intracellular iron accumulation, as
this biomolecule binds to FPN, internalizing this receptor
(29). LPS and pro-inflammatory cytokines stimulate hepcidin
production, inducing hypoferremia, a mechanism involved in the
anemia of chronic inflammation pathogenesis (30). Interestingly,
astrocytes were shown to induce neuronal death in response
to LPS-activated microglia and to synthesize hepcidin via the
IL-6/STAT3 pathway, likely linking hepcidin to A1 astrocytes
(31). In addition, iron activates nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-kB), a transcription factor
involved in innate immune training and inflammation (27).
Microglia are yolk-sac-derived myeloid cells, comprising up
to 20% of the total brain glial cell population (32). Their main
function consists of brain parenchyma surveillance, searching
for endogenous or exogenous danger signals to which they
respond by activation (33). Another major function of microglia,
assisted by astrocytes, consists of tolerization or acceptance of
self-molecules, food, commensal microbes, and the fetus. This
task is accomplished by phagocytosis via prompt clearance of
molecular debris, including dead or dying cells that were shown
to trigger inflammation and autoimmunity when allowed to
accumulate (34). Taken together, disruption of phagocytosis can
lead to unchecked inflammation, impaired immune tolerance
and autoantibodies against self-components. Indeed, increased
levels of autoantibodies were documented in AD, suggesting that
autoimmunity may play a role in this disorder (35).
THE TRAINED ARM OF INNATE IMMUNITY
Pathogen-mediated iron sequestration is an effective mechanism
that protects the host against bacteria and malignancies at the
risk of inflammation and ROS triggered by increased intracellular
iron (36). To lower this risk, iron must be properly stored into
the cytosolic and mitochondrial ferritin, a process that may be
disrupted by inflammation and age-related pathology. In the
CNS, pathogen-mediated iron sequestration is initiated upon
detection of PAMPs and/or DAMPs by microglia and astrocyte,
followed by the release acute phase proteins, including hepcidin
and lipocalin-2 (LCN-2), to internalize iron (29, 37).
Aging augments the expression of hepcidin and LCN-2,
which along with impaired ferritinophagy, increases the risk of
free intracellular iron and prolonged inflammation via NLRP3
inflammasomes activation (16, 38). Both hepcidin and LCN-
2 have been associated with neurotoxicity and AD, despite
some studies describing them as neuroprotective (39–42). These
findings are contradictory in appearance only because hepcidin
and LCN-2 may have both beneficial and detrimental effects,
depending on the phase of inflammation. For example, during
the acute phase, iron sequestration may be adaptive as it is
denied to pathogens, limiting infection and inflammation. On
the other hand, with chronic inflammation and increasing
age, intracellular iron may become detrimental as it activates
NLRP3 likely overwhelming immune tolerization and triggering
neuronal loss. In addition, iron also activates NF-kB implicated
in tolerization disruption and autoimmunity when in excess
or inappropriately activated (43) (Figure 1). Iron may impair
immune tolerance directly by altering microglial secretome,
enhancing the release of TNF-alpha, IL-1, and C1q, cytokines that
promote A1 astrocytes (1). Indeed, the pathological phagocytosis
that A1 cells engage in may reflect the loss of neuronal
and oligodendrocytic tolerization. Interestingly, a different
study reported A1 astrocytes’ upregulation in healthy elderly
individuals, linking these cells to the chronic inflammation of
aging or inflammaging, considered by some an AD prodrome
(44, 45). Moreover, a novel study found that glucagon-like
peptide-1 receptor (GLP1R) agonists can block the conversion of
trophic to A1 astrocytes, suggesting that Diabetes mellitus type
2 treatments, including liraglutide, may benefit inflammaging
and AD (46). Interestingly, liraglutide was documented to lower
inflammatory responses by decreasing the expression of NLRP3,
suggesting that this drug may function as an inflammasome
inhibitor (47).
Inflammasomes are cytosolic multiprotein complexes
activated in innate immune cells in response to PAMPs or
DAMPs (16, 48). Inflammation is ignited by the inflammasome
assembly with caspase1-induced maturation of interleukin-1β
and IL-18 which in turn activate multiple inflammatory pathways
(49) (Figure 2). NLRP3 inflammasomes, abundantly expressed
by microglia and astrocytes, may play a major role in AD as they
can be activated by beta amyloid, iron and ROS, maintaining
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FIGURE 2 | NLRP3 inflammasomes activation: iron-damaged mitochondria,
acting as a DAMP, directly or via ROS triggers inflammation by activating
NLRP3 inflammasomes. Inflammasomes are comprised of a sensor, the
nucleotide-binding oligomerization domain (NOD), in this case the (NOD)-like
receptor protein 3 (NLRP3), apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC) and caspase-1 which, upon
stimulation, assemble and cleave premature IL-1 beta and IL-18 into their
biologically active forms, activating microglia (trained immunity).
chronic inflammation (48, 50, 51). Indeed, continuous immune
training in inflammaging and ADwas associated with perpetually
elevated NLRP1 and NLRP3 mRNA levels (52–54). Similarly,
chronic NLRP3 activation was associated with atherosclerosis
andWestern diets, linkingmetabolism and chronic inflammation
(55, 56).
Recently the mitochondrion was identified as the interface
connecting immunity and metabolism as this organelle contains
the mammalian target of rapamycin (mTOR), a protein
involved in shifting the metabolic gears from oxidative
phosphorylation (OXPHOS), characterizing tolerized immunity,
to aerobic glycolysis, marking immune training (11). Iron has
been demonstrated to induce mitochondrial damage, probably
lowering OXPHOS and prompting NLRP3 inflammasome
assembly and microglial training (57, 58) (Figure 2). In fact,
iron-disrupted OXPHOS may leave aerobic glycolysis as the
only metabolic option for microglia and a possible source
of neuroinflammation in AD. Along these lines, a recent
study described a direct cross-talk between mTOR and iron
metabolism, suggesting a connection between this biometal
and aerobic glycolysis (59, 60). Mitophagy or elimination of
damaged mitochondria (including that which is iron-induced)
was reported to inhibit NLRP3 and lower immune training in
AD models, pointing to mitophagy as a potential AD treatment
(61–64). Interestingly, liraglutide, a GLP-1R agonist, was shown
to promote mitophagy in addition to, or because of NLRP3
inhibition, indicating a potential “off label” use of this drug (65).
A recent preclinical study linked the NLRP3 component,
apoptosis-associated speck-like protein containing a caspase
recruitment domain (ASC), with the prion-like seeding of
beta amyloid (66). Similarly, in a previous study, ASC was
reported as capable of migrating through the extracellular
space (67). Another novel study found a link between NLRP3
inflammasomes and prion disease (68). Furthermore, multiple
studies over the past decade established a close connection
between various forms of prion diseases and autoimmunity,
suggesting a common denominator (69, 70). Interestingly, iron
was associated with both prion disease and autoimmunity, and
chelation was found therapeutic in CNS autoimmune disorders,
including MS and experimental autoimmune encephalomyelitis
(EAE) (71–74). For example, brain iron dyshomeostasis was
demonstrated in prion disease patients, while another study
found a higher incidence of autoimmune disorders in individuals
with hemochromatosis (71, 74). A preliminary study found that
deferiprone, a BBB-crossing iron chelator, was therapeutic in
MS patients (73). Moreover, some iron chelators were found
beneficial in AD and Parkinson’s disease (PD), possibly pointing
to the role of autoimmune inflammation in these disorders (75–
77). Indeed, over the past decade, several studies have associated
autoimmunity with AD as serum and CSF autoantibodies against
β-amyloid, tau, ceramide and adenosine triphosphate (ATP)
synthase were detected in this disorder (35, 78–82). Interestingly,
these molecules were also associated with iron and NLRP3,
making it worthwhile to search for ASC autoantibodies in AD
(83–87).
THE TOLERIZED ARM OF INNATE
IMMUNITY
Effective protection from pathogens and malignant cells is an
important function of the innate immune system, but an equally
important task is protection against autoimmune inflammation
by maintaining immunologic tolerance to self-structures, food,
the fetus, and commensal bacteria. Tolerized immunity or
absence of immune responses to repeated or prolonged LPS
stimulation was originally described in rodents which survived
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the administration of a lethal endotoxin dose after previous
exposure to sublethal concentrations (88). The adaptive role of
this mechanism in the CNS may include “tolerating” elevated
levels of LPS demonstrated in the brains of aging individuals
and AD patients (2). Indeed, aging and AD have been associated
with increased gram-negative bacteria titers in the GI tract and
gums (89). For example, individuals with AD were found to have
three times higher LPS blood levels compared to controls (90).
Interestingly, novel studies have shown that B. fragilis generates
a structurally different LPS (BF-LPS), that selectively inhibits
immune tolerization, possibly contributing to the pathogenesis
of both autoimmune disorders and AD (25, 26).
Aside from the LPS response, brain tolerized immunity
may serve the purpose of inhibiting inflammation during
phagocytosis of apoptotic cells, synapses, or damaged
endogenous molecules, a process we define as tolerant
phagocytosis (91, 92). Preclinical studies have shown that
disruption of this pathway and accumulation of molecular
debris activates autoimmune inflammation, inflicting neuronal
damage (93, 94). A novel study has reported that LPS down-
regulates the expression of the triggering receptor expressed on
myeloid cells 2 (TREM2), the microglial receptor associated with
immune tolerance (95) (Figure 1). Apolipoprotein E (ApoE)
is a TREM2 ligand and their interaction may be necessary for
tolerant phagocytosis (96–98). Indeed, TREM-2 blockade was
demonstrated to exacerbate EAE and MS, linking this receptor
to the CNS autoimmune disorders (99, 100).
A recent pivotal study established the existence of an ApoE-
TREM-2 axis which under normal circumstances engenders
tolerized or homeostatic microglial phenotypes (101). In
contrast, a dysfunctional ApoE-TREM-2 axis was associated
with deficient tolerization and unopposed inflammation. For
example, ApoE4 isoform, linked to late onset AD, presents with
poor TREM-2 binding, leading to the activation of NLRP3 and
immune training instead of tolerization (102, 103).
In AD, the tolerized arm of innate immunity appears to be
impaired as persistently elevated LPS brain levels fail to induce
tolerance, probably triggering the autoimmune elimination of
neurons and oligodendrocytes via A1 astrocytes (1, 2, 98, 104).
Moreover, LPS elevation in AD was linked to iron as dormant
microbes, including B. fragilis, may survive in the CNS in
an inactive state limited by the lack of free iron (6). During
FIGURE 3 | An overview of the trained and tolerized arm of innate immunity. Trained arm: excess iron and ROS trigger activation of NLRP3 inflammasomes with
excessively trained microglia and neuroinflammation that may override tolerization. In addition, iron lowers ApoE expression and alters C1q and C3, further impairing
tolerization via ApoE -TREM-2 axis. Both excessive immune training or insufficiently tolerized microglia may trigger neuronal loss. ApoE4 isoform binding C1q triggers
inappropriate elimination of healthy synapses by astrocytes, likely by promoting the A1 cells.
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aging, impaired iron homeostasis provides these microbes with
enough metal to resume their growth and LPS shedding, possibly
explaining the LPS upregulation observed in AD (105). Indeed,
iron may facilitate B. fragilis resuscitation in the brain as this
microbe was shown to require iron or heme for surviving outside
of the GI tract (106). In addition, iron-induced endothelial cells’
damage may open the BBB (a property exploited in the treatment
of gliomas), allowing microbial passage (107, 108). On the other
hand, iron chelators were demonstrated to inhibit B. fragilis
growth, lowering LPS brain levels, perhaps explaining some of the
beneficial effects of these compounds in AD (109). In addition,
LPS, not only promotes ferritinophagy, but also the astrocytic
expression of hepcidin via IL6/STAT3, further augmenting the
cellular free iron pool along with the chances of dormant bacterial
resuscitation (31).
At the molecular level, tolerized immunity was shown to be
associated with microglial TREM-2 receptors, interacting with
anti-inflammatory molecules, including ApoE, and complement
components C1q/C3 (110–112) (Figure 3). In addition, tolerized
immunity was shown to be modulated by iron-dependent
hypoxia-inducible factor 1α (HIF-1α), suggesting another
tolerization target (113).
Under physiological circumstances C1q and C3 facilitate
phagocytosis by tagging dysfunctional synapses for engulfment
by microglia and astrocytes (114, 115). In addition, C1q
enhances immune tolerance and inhibits NLRP3-induced
immune activation (116). Pathologically, deficient C1q was found
in over 90% of systemic lupus erythematosus (SLE) patients,
linking this protein to autoimmune inflammation (117). In
contrast, ApoE4-induced C1q upregulation was associated with
inappropriate elimination of healthy synapses by astrocytes,
connecting this phenomenon to autoimmunity and the A1
cells (118). Indeed, the development of anti-C1q antibodies
may comprise a novel therapeutic strategy for both AD and
autoimmunity (10).
Iron disrupts tolerized immunity by lowering ApoE
expression in microglia, impairing the ApoE-TREM-2 axis
and amyloid plaque phagocytosis (119–121). Indeed, ApoE-
immunoreactive microglia were found closely associated with
senile plaques, suggesting a key role in AD pathology (122).
In addition, iron disrupts tolerized immunity by upregulating
C3 and altering the C1q expression, likely preventing their
ApoE binding (123, 124). Indeed, C3 upregulation was linked
to increased beta amyloid and phosphorylated tau, linking once
more iron to AD pathogenesis (110, 125) (Figure 3). Other recent
studies connected iron-upregulated C3 with the A1 astrocytes
by demonstrating high complement levels in astrocyte-derived
exosomes obtained from AD patients (114, 126).
Aside from ApoE and C1q/C3, iron inhibits α-secretase
or ADAM-10, the enzyme involved in the generation of
soluble TREM-2 (sTREM-2), linking again this biometal to
autoimmunity (102, 123, 124, 127–129) (Figure 4).
Adenosine-triphosphate (ATP) synthase, the mitochondrial
enzyme involved in ATP biosynthesis, is a newly identified AD
target, especially because extracellular ATP (eATP) is a potent
NLRP3 activator associated with autoimmune disorders (81–
85). This is relevant as preclinical studies show iron-associated
FIGURE 4 | A closer view of microglial ApoE-TREM-2 axis: ApoE, C1q, and
C3 engender tolerant phagocytosis (lack of inflammatory response during the
clearance of damaged self-components). Iron disrupts this process by
promoting prolonged inflammation that overrides immune tolerization. In
addition, iron impairs tolerization by altering C1q and ApoE along with C3
upregulation. Iron also inhibits alpha secretase (ADAM-10) which cleaves
tolerant TREM-2 receptor into sTREM-2, likely impairing phagocytosis.
DAP-12 is a TREM-2 adapter, anchoring this receptor into the cell membrane.
ADAM-10 is the same enzyme that cleaves amyloid precursor protein (APP),
preventing the formation of amyloid-beta peptide.
augmentation of F1 and F0 components of ATP synthase with
loss of mitochondrial ATP, possibly suggesting ATP displacement
to the extracellular compartment (130). In addition, iron-
binding protein, lactoferrin clears eATP, presenting with a
beneficial role in AD (see the section on exosomes and
Inflammasomes). Furthermore, blockade of purinergic receptors
P2Y1 was associated with improved cognition in AD models,
while P2X7 inhibition was found beneficial in autoimmune
disorders, linking eATP and iron to impaired immune tolerance
(87, 130, 131).
THE INNATE-ADAPTIVE CONTINUUM
Novel preclinical studies indicate a close cooperation between the
innate and adaptive immune systems via NLRP3 inflammasomes
and IL-1β (132, 133). Microglia and astrocytes communicate
extensively with peripheral lymphocytes, inducing their
activation and CNS migration (10, 134). IL-1β is known for
increasing BBB permeability, facilitating the infiltration of
peripheral cytotoxic T-cells (CTCs) into the CNS (135). In
addition, iron is known for altering the BBB by inflicting
endothelial cells damage, facilitating peripheral cells access to the
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CNS (107). In addition, peripheral lymphocytes may access the
brain via the newly discovered CNS-draining lymphatics (17).
The newly arrived cells were shown to activate NLRP3,
attracting more blood-borne immune cells into the brain (136).
On the other hand, tolerized glia may orchestrate the CNS import
of T-regs or the newly identified regulatory B1a cells which in
turn lower microglial training (137–140). In addition, B-cells
have been known to facilitate the recruitment of T-regs to the
CNS, augmenting their immunosuppressive activities (141).
T-regs, the preservers of immune tolerance, were found to
delay AD progression, linking this condition to autoimmune
inflammation (142, 143). The anti-inflammatory IL-10 released
by tolerized microglia and T-regs was demonstrated to negatively
regulate iron metabolism, possibly explaining the beneficial role
of Tregs in AD (144). In addition, IL-4 also regulates iron
metabolism and promotes immune tolerance (145). Indeed,
iron has been shown to facilitate the CNS infiltration of
peripheral CTCs, while iron chelation produces the opposite
effect (146). Furthermore, IL-10 was demonstrated to inhibit
aerobic glycolysis, the metabolic driver of trained immunity,
promoting the tolerant OXPHOS (144, 147, 148). Interestingly,
a recent preclinical study discovered a CNS population of
cerebral T-regs, documenting that aside from blood borne, the
brain maintains its own tolerogenic lymphocyte population
(139). Other novel studies demonstrated the existence of various
T-regs subpopulations, expressing different co-inhibitory T-
cell receptors, including the T-cell immunoglobulin and ITIM
Domain (TIGIT) that regulates immunity exclusively via iron-
lowering IL-10, linking this receptor to iron downregulation
(149, 150).
Co-inhibitory receptors, including cytotoxic T-lymphocyte
associated protein 4 (CTLA-4), programmed cell death protein
1 (PD-1), lymphocyte-activation protein 3 (Lag-3), and TIGIT
play an essential role in the prevention of autoimmune disorders
by promoting tolerized responses (151, 152). A growing body
of evidence reveals that dysfunctional co-inhibitory receptors
may contribute to AD neuroinflammation as under normal
circumstances they function to inhibit inflammation-generating
co-stimulatory signals (153). For example, upregulation of PD-
1 expressed on both microglia and T-regs, was found beneficial
in AD animal models (154). Another study demonstrated that
non-PD-1 expressing T-regs were upregulated in mild cognitive
impairment (MCI), demonstrating the beneficial role of PD-1
receptors in preventing the development of full-blown AD (155).
Indeed, tolerized microglia also express PD-1, activating T-regs
and probably facilitating their CNS import (156, 157).
These findings suggest that other co-inhibitory receptors,
including TIGIT, may activate T-regs. Interestingly, a recent
study found elevated TIGIT in the peripheral blood of healthy
elderly individuals (158). As upregulated A1 astrocytes were also
found in normal aging, TIGIT and A1 may comprise novel AD
risk markers (45). In addition, as TIGIT modulates immunity via
the iron-lowering IL-10, this receptor may be elevated in normal
aging in a compensatory manner in response to iron overload
(149). TIGIT is yet to be demonstrated on glial cells, however
like PD-1, it may be a coordinator of adaptive and immune
responses.
Taken together, this data suggests that innate and adaptive
immunity operate on a continuum as trained immunity may
activate CTCs, while tolerized immunity the T-regs, therefore
targeting trained and tolerized immunity may lower the CNS
infiltration of peripheral lymphocytes.
MICROGLIAL REPROGRAMING: TRAINED
AND TOLERIZED THERAPIES
The recent FDA approval of immune training-inducers
prompted research for similar therapies for cancer and
neurodegeneration (18). Immune stimulatory vaccines,
comprised of antigen and pro-inflammatory molecules, activate
TLRs or NLRP3, inducing immune activation. These therapeutics
have been utilized to train APCs and reverse cancer or sepsis-
induced T cell anergy. Iron as an inducer of trained immunity
has been utilized to activate TAMs and several nanoparticles
are currently being designed for its delivery (14). On the
other hand, the development of specific tolerized therapies,
including “inverse vaccines,” capable of improving pathology
without causing generalized immunosuppression, has been
vexing (20). The same is true regarding the first-generation AD
vaccines, like AN1793, based on anti-Aβ1-42 antibodies which
was abandoned due to adverse effects (159). However, despite
these draw backs, a new generation of AD vaccines, including
anti-C1q mentioned above, are currently being developed.
Since neuroinflammation represents the predominant pathology
in many neurodegenerative and even psychiatric disorders,
de-escalating iron-trained microglia may comprise an effective
treatment strategy. Indeed, the anti-inflammatory iron chelator
deferiprone is currently in phase 2 trials for AD (15, 160).
Deferiprone may have a dual mechanism of action, lowering
trained immunity and augmenting tolerization, suggesting that
simultaneously targeting both arms of innate immunity may
yield better therapeutic outcomes than addressing each one
in isolation. Another dual-mechanism-of-action compound,
hydroxamic acid, is a promising histone deacetylase-6 inhibitor
(HDAC6i) which presents with the added benefit of being an iron
chelator (161, 162). Histone deacetylases are enzymes involved
in the removal of acetyl groups from histone proteins, altering
the chromatin landscape and gene expression. HDACs have been
associated with AD pathogenesis, while some HDACis were
found to improve cognition (163, 164). In addition, selective
HDAC inhibitors were shown to suppress LPS-trained microglia
via IL-6 and TNF-α, suggesting a therapeutic potential in AD
neuroinflammation (165). Moreover, HDACs 1 and 2 inhibitors
are augmenters of microglial β amyloid phagocytosis, linking
these compounds to the immuno-metabolic reprograming via
OXPHOS augmentation (165, 166).
INFLAMMASOME INHIBITORS
NLRP3 inhibition to lower immune training and the subsequent
neuroinflammation is an emerging therapeutic strategy in AD
and traumatic brain injury (TBI) (167–169).
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Purinergic receptor blockers, ASC inhibitors,
diarylsulphonylurea inhibitors, β-sulfonyl nitrile compounds,
and caspase-1 blockers are the broad categories of recently
developed NLRP3 inhibitors (170, 171). The most studied
compound, MCC950 is a diarylsulphonylurea inhibitor, a potent
anti-inflammatory drug and a facilitator of β amyloid clearance
in AD animal models (172). Another recently developed
molecule, OLT1177, is a β-sulfonyl nitrile which inhibits NLRP3
by limiting ROS generation after LPS challenge. This compound
is currently in phase I clinical trials.
Suppressing NLRP3 by ASC inhibition is an attractive
AD strategy as ASC was recently found to disseminate β
amyloid throughout the CNS (66, 172). Interestingly, saxagliptin,
a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases
plasma GLP-1 concentration, appears to selectively inhibit ASC,
suggesting a role in preventing the spread of AD pathology (173).
This is significant since GLP-1R agonists were found to inhibit
the conversion of trophic into A1 astrocytes, probably linking
ASC to this neurotoxic phenotype (1, 46). Moreover, Tranilast,
an anti-allergic drug derived from tryptophan, was also reported
to selectively inhibit ASC, suggesting a preventive potential in AD
(174).
OF EXOSOMES AND INFLAMMASOMES
Exosomes are (50–150 nm) extracellular nanovesicles released by
most cell types, including neurons and glia, which can carry
molecular cargos and trigger functional changes in target cells.
Exosomes cross the BBB, facilitating the transfer of inflammation
as they can carry a variety of peripheral molecules, including
inflammasome-derived proteins (175, 176).
Exosomes, involved in innate immune cells’ cross talk,
participate in microglial training or tolerization by augmenting
or lowering neuroinflammation, depending on their cells
of origin (17, 177, 178). Novel studies have found that
neuronal exosomes have beneficial effects, while astrocytes-
derived exosomes (ADE) are mostly detrimental, inducing
neurodegeneration. Neuronal exosomes present with the
adaptive function of clearing β amyloid by delivering it to
microglia for phagocytosis. For this reason, pharmacological
facilitation of neuronal exosomes’ synthesis could be developed
into an AD therapy (176). For example, designer neuronal
exosomes were recently developed and utilized in animal
models of Parkinson’s disease (170). Interestingly, microglial
cells were shown to release exosomes that were previously
reported to originate from B cells and dendritic cells, suggesting
pro-inflammatory roles (179). CNS autoimmune disorders have
been associated with exosomes transporting histocompatibility
complex (MHC) class II proteins released by interferon-γ
activated microglia (180).
ADE were shown to promote the conversion of trophic to
A1 astrocytes by releasing exosomes containing complement
components C1q and C3 (126, 181–183). Preventing ADE
release may comprise another potential AD strategy. Moreover, a
novel study has demonstrated that excessive interstitial ATP can
facilitate the generation of A1 astrocytes, suggesting clearance
of ATP from the extracellular space (ECS) as a potential AD
treatment modality (174). Interestingly, the natural iron chelator,
lactoferrin, was found to facilitate the ECS removal of ATP,
indicating a novel therapeutic application (184). Indeed, a recent
study suggested that engineered lactoferrin-containing exosomes
could accomplish this goal (185).
HISTONE DEACETYLASES INHIBITORS
(HDACI)
Innate immune cells are endowed with an epigenetically
regulated memory of previous antigen encounters, suggesting
that epigenome manipulation may comprise an efficient
reprograming strategy in these cells (17). Acetylation and
deacetylation of DNA and histone proteins are the most
studied epigenetic mechanisms regulating innate immune cells.
Indeed, HDACi were shown to lower the LPS-induced microglial
training, promoting tolerization (165). For example, valproic
acid, a HDACi utilized in the treatment of bipolar disorder
and epilepsy, was shown to downregulate the mammalian
target of rapamycin (mTOR), restoring OXPHOS, the driver
of immune tolerance (11, 186–188). Furthermore, HDACi were
recently shown to augment astrocytic ApoE secretion (189).
Since ApoE inhibits NLRP3 activation, HDAC inhibition may
have a potential therapeutic value in the fight against AD
neuroinflammation (Figure 3).
HDACi are facilitators of ferritin storage, lowering
intracellular free iron and the risk of NLRP3 activation
(161, 190). In addition, HDACi reverse the iron-induced
augmentation of glycogen synthase kinase-3β (GSK3β), a pro-
inflammatory enzyme implicated in AD (191, 192). GSK-3β
inhibitors, including lithium, were shown to promote immune
tolerance, suggesting a therapeutic role in lowering iron levels
(193–195). Interestingly, the tolerizing receptor TREM-2 is a
negative regulator of GSK-3β, further associating this protein
with decreasing iron-induced neuroinflammation (191, 196).
CO-INHIBITORY T-CELL RECEPTORS IN
AD
Dysfunctional co-inhibitory receptors may contribute to AD
neuroinflammation as under normal circumstances, they
block co-stimulatory signals, lowering inflammation (153).
For example, stimulation of PD-1 receptors, expressed on
both microglia and T-regs, was found beneficial in AD animal
models (154). On the other hand, increased number of non-
PD-1 expressing T-regs in MCI, shows the importance of this
co-inhibitory receptor in AD prevention (155).
T cell activation by APCs is crucial for mounting adequate
adaptive immune responses. In the CNS,microglia and astrocytes
can become APCs, engendering immunologic synapses with
peripheral T cells (10). The proliferation, differentiation, and
migration of these cells is triggered by the interplay between
co-stimulatory and co-inhibitory signals which fine tune T
cell responses (197). For example, the co-stimulatory receptors
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promote effector T-cells function, while co-inhibitory receptors
function to inhibit co-stimulatory signals, promoting T-regs (6).
Activation of co-inhibitory receptors, including CTLA-4,
PD-1, LAG-3, TIM-3, and TIGIT, induce immune tolerance,
therefore their stimulation would be beneficial in autoimmune
disorders (198). On the other hand, their blockade was shown to
train TAMs in a manner similar to iron and eliminate cancer cells
(199). Interestingly, TIGIT competes with the co-stimulatory
signal CD226 for a common ligand CD155, suggesting that
promoting the TIGIT-CD155 axis may lower intracellular iron
as TIGIT operates exclusively via the iron-lowering IL-10 (200).
Indeed, IL-10 or CD-155 loaded exosomes may enhance the
co-inhibitory receptor TIGIT, lowering microglial intracellular
iron. In addition, the CD226 genetic variant, Gly307Ser, was
associated with several autoimmune disorders, suggesting that
CD 226 inhibition may facilitate tolerized immunity and benefit
the treatment of these conditions as well (201, 202).
TOLERIZED IMMUNITY AND
ACETYLCHOLINESTERASE INHIBITORS
Acetylcholinesterase inhibitors (AChEIs) are cholinergic
compounds widely utilized in AD. AChEIs, including
donepezil, rivastigmine, and galantamine function by inhibiting
cholinesterase, the acetylcholine-degrading enzyme, increasing
its synaptic availability in the cholinergic tracts. Some of these
drugs may be modulators of trained or tolerized immunity as
they oppose iron-induced NLRP3 activation and the inhibition
of ADAM-10, the protective α-secretase, in charge of cleaving
both TREM-2 and APP (203–205) (Figure 4). In addition, α7-
and α9 nicotinic acetylcholine receptor (nAChR) agonists were
found to lower autoimmune inflammation, by augmenting
tolerization (206, 207). Moreover, activation of α7nAChRs was
found to reverse post-surgical cognitive impairment, suggesting
that AChEIs-linked cognitive enhancement may be due to their
anti-inflammatory actions (208). On the other hand, a recent
study demonstrated that iron and ROS can inhibit α7nAChRs
signaling, likely disrupting tolerized immunity (209, 210).
Interestingly, conjugation of an AChEI, such as galantamine,
with the natural iron chelator, lactoferrin, was recently proposed
as an AD therapy (211).
TOLERIZED IMMUNITY AND SELECTIVE
SEROTONIN REUPTAKE INHIBITORS
(SSRIs)
Serotonin reuptake inhibitors (SSRIs) are widely prescribed
antidepressant drugs that block 5-hydroxytryptamine reuptake in
the presynaptic neurons of brain serotonergic tracts, augmenting
the synaptic availability of this neurotransmitter. However, these
compounds were found to also lower trained immune responses.
For example, a recent study indicated that the SSRI, fluoxetine
reduces the central and peripheral levels of IL-1β by inhibiting
NLRP3 (212, 213).
Another group demonstrated the existence of a cross talk
between the brain innate immunity and serotonin signaling,
possibly linking major depressive disorder with NLRP3
activation (214). Along the same lines, it was recently shown that
indoleamine 2,3-dioxygenase-1 (IDO-1), an enzyme associated
with tryptophan catabolism, is abundantly expressed by
microglia and astrocytes, connecting serotonergic signaling with
tolerized immunity (215). IDO-1 induces immune tolerance by
processing tryptophan to L-kynurenine, an inhibitor of immune
cells’ proliferation and maturation (216). IDO-1 is known for
orchestrating mother’s immune acceptance of the fetus, however
some bacteria and cancers were found to exploit this pathway
(217, 218). Indeed, an IDO vaccine to block cancer-induced
immune tolerance is currently under development (219).
Moreover, IDO-1 contributes to the biosynthesis of quinolinic
acid (QUIN), a neurotoxic tryptophan catabolite that was linked
to AD pathogenesis (220). Interestingly, iron-QUIN complexes
were demonstrated in this neurodegenerative disorder, indicating
that QUIN toxicity may be iron-related (221, 222). QUIN was
demonstrated to activate microglia and astrocytes, resulting in
neuronal death, possibly by inducing A1 cells (223–225).
CONCLUSIONS
The healthy immune system must keep trained and tolerized
immunity in balance to ensure effective defenses against
pathogens andmalignancies, while at the same time accepting the
self-components, food, the fetus, and commensal microbes. Iron
interferes with this process as it triggers a competition between
the host and pathogens. Both biological systems have developed
mechanisms to capture iron and deny it to the opposing side. The
innate immune cells sequestrate iron to restrict its availability
to pathogens, but elevated intracellular iron increases the risk
of mitochondrial damage, ROS generation, and autoimmune
inflammation.
Aging and iron are associated with increased permeability of
both GI and brain microvessels, allowing gut microbes, including
B. fragilis, to migrate into the CNS and shed LPS, disrupting
immune tolerization. Manipulation of trained and tolerized
immunity, especially via exosomes and nanoparticles loaded with
iron chelators could represent future AD strategies (76). Indeed,
iron-oxide loaded exosomes for magnetic hyperthermia have
been successfully used in oncology (226).
Tolerogenic immunization also known as “inverse vaccines,”
can for example, utilize CD-155 loaded exosomes to enhance the
co-inhibitory receptor TIGIT and lower AD neuroinflammation
(227). In addition, nanoparticles containing NLRP3-inhibitors,
HDACi or ASC blockers may soon become parts of the AD
armamentarium.
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